TreatIng Microalbuminuria Over 24 Weeks in Subjects With or Without Type 2 Diabetes or HYpertension

Inclusion Criteria: * Age 45 to 80 years * Persistent urinary albumin:creatinine ratio (UACR) ≥ 2.5 mg/mmol (\~25 mg/g) * Willing to sign informed consent Exclusion Criteria: Diagnosis of type 1 diabetes mellitus * eGFR \< 25 ml/min/1.73m2 * UACR \> 3500 mg/g * Concurrent treatment with SGLT2 inhibitor * Receiving immunosuppressive therapy within 6 months prior to enrolment * History of diabetic ketoacidosis * Active malignancy aside from treated squamous cell or basal cell carcinoma of the skin. * Initiation or changes in the dose of interventions in the renin-angiotensinaldosterone- system, diuretics, GLP-1 receptor agonists within 6 weeks of screening will not be allowed. * Any medication, surgical or medical condition which might significantly alter the absorption, distribution, metabolism, or excretion of medications including, but not limited to any of the following: * History of active inflammatory bowel disease within the last six months; * Major gastrointestinal tract surgery such as gastrectomy, gastroenterostomy, or bowel resection; * Gastro-intestinal ulcers and/or gastrointestinal or rectal bleeding within last six months; * Pancreatic injury or pancreatitis within the last six months; * Evidence of hepatic disease as determined by any one of the following: ALT or AST values exceeding 3x ULN at the screening visit, a history of hepatic encephalopathy, a history of esophageal varices, or a history of portocaval shunt; * Evidence of urinary obstruction or difficulty in voiding at screening * History of severe hypersensitivity or contraindications to dapagliflozin * Subjects who, in the assessment of the investigator, may be at risk for dehydration or volume depletion that may affect the interpretation of efficacy or safety data * Participation in any clinical intervention study within 3 months prior to initial dosing. * History of drug or alcohol abuse within the 12 months prior to dosing, or evidence of such abuse as indicated by the laboratory assays conducted during the screening. * History of noncompliance to medical regimens or unwillingness to comply with the study protocol. * Any surgical or medical condition, which in the opinion of the investigator, may place the patient at higher risk from his/her participation in the study, or is likely to prevent the patient from complying with the requirements of the study or completing the study. * Pregnancy or breastfeeding